Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03000140
Other study ID # Number 03052015
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 2015
Est. completion date February 2017

Study information

Verified date October 2018
Source Universidad Santo Tomas
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Despite exercise training decrease blood pressure in 'average' terms, there is a wide interindividual variability after exercise training, being yet unknown what mode of exercise (e.g. endurance, strength, concurrent, or high intensity interval training) produce more/less non-responder (NR) prevalence (i.e., percentage of subjects who experienced a non-change/worsened response after training in some outcome).


Description:

Despite exercise training decrease blood pressure in 'average' terms, there is a wide interindividual variability after exercise training, being yet unknown what mode of exercise (e.g. endurance, strength, concurrent, or high intensity interval training) produce more/less non-responder (NR) prevalence (i.e., percentage of subjects who experienced a non-change/worsened response after training in some outcome).


Recruitment information / eligibility

Status Completed
Enrollment 142
Est. completion date February 2017
Est. primary completion date December 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years to 40 Years
Eligibility Inclusion Criteria:

- Written informed consent;

- Interested in improving health and fitness;

- Systolic blood pressure > 120 mmHg and < 140 mmHg, and/or DBP = 80 and < 90 mmHg according with standard classification;

- No drug therapy during the previous 3 months;

- Body mass index (BMI) 25 and 35 kg/m2); (c) physically inactive (according to the International Physical Activity Questionnaire previously validated in Chilean population)

- Normal /mild altered lipid profile (total cholesterol [TC] ~200 and =250 mg/dL, low-density lipids [LDL-C] ~140 mg/dL and =200 mg/dL, high-density lipids [HDL-C] =20 and ~40 mg/dL, triglycerides ~150 and =250 mg/dL) according with standard classification.

Exclusion Criteria:

- Cardiovascular contraindications to exercise histories of stroke;

- Asthma and chronic obstructive pulmonary disease;

- Musculoskeletal disorder such as low back pain;

- Smokers in the last 3 months were not included in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
High Intensity Interval Training
High Intensity Interval Training pre-hypertensive group; Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 16 weeks.
Control group
Moderade Intensity Interval Training pre-hypertensive group; Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 16 weeks.

Locations

Country Name City State
Chile Cristian Alvarez Osorno

Sponsors (5)

Lead Sponsor Collaborator
Universidad Santo Tomas Healthcare Center Tomas Rojas, Universidad del Rosario, Universidad Pública de Navarra, University of Los Ríos

Country where clinical trial is conducted

Chile, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline in systolic blood pressure and diastolic blood pressure After this, we calculated the delta changes in both variables and classified to all subjects in responders (R) and non-responders (NR) to decrease systolic or diastolic blood pressure. Baseline and 16 weeks immediately after the interventions ends
Secondary Change from Baseline in body mass Baseline and 16 weeks immediately after the interventions ends
Secondary Change from Baseline in body mass index BMI will be calculated as the body weight in kilograms divided by the square of the height in meters. Baseline and 16 weeks immediately after the interventions ends
Secondary Change from Baseline in waist circumference Baseline and 16 weeks immediately after the interventions ends
Secondary Change from Baseline in fat mass Baseline and 16 weeks immediately after the interventions ends
Secondary Change from Baseline in heart rate at rest Baseline and 16 weeks immediately after the interventions ends Baseline and 16 weeks immediately after the interventions ends
Secondary Change from Baseline in fasting glucose Baseline and 16 weeks immediately after the interventions ends
Secondary Change from Baseline in lipids Lipid profile (low-density cholesterol, total cholesterol, high-density cholesterol and triglycerides) Baseline and 16 weeks immediately after the interventions ends
Secondary Change from Baseline in one maximum repetition strength test of leg-extension exercise Baseline and 16 weeks immediately after the interventions ends
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A